Form 4: Exelixis Director Julie Smith Receives Significant RSU Grant

Exelixis, Inc. Director Julie Smith was granted 9,812 restricted stock units (RSUs) on May 29, 2025, as part of her compensation.

Summary

• Julie Smith, a Director of Exelixis, Inc. (EXEL), received a grant of 9,812 Restricted Stock Units (RSUs) on May 29, 2025.
• These RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan, with each RSU being the economic equivalent of one share of Exelixis common stock.
• The RSUs are scheduled to vest 100% on May 29, 2026, contingent upon Ms. Smith's continuous service through that date.
• Following this transaction, Ms. Smith's beneficial ownership stands at 20,590 shares, which includes 19,827 shares of Common Stock that will be issued upon the vesting of previously granted RSUs.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is generally a positive sign of aligning management interests with shareholders. There are no negative financial implications or red flags within the document itself.

Positives

• The grant of 9,812 Restricted Stock Units (RSUs) to a director aligns her interests with those of the company's shareholders.
• The vesting schedule, contingent on continuous service, encourages long-term commitment and retention of key board members.
• The transaction is part of the established Exelixis, Inc. 2017 Equity Incentive Plan, indicating a structured and transparent approach to director compensation.

Risks

• The vesting of the 9,812 RSUs is subject to the reporting person's continuous service through May 29, 2026, meaning the shares are not guaranteed if service ceases before that date.

Future Outlook

The document indicates a future milestone for the director's equity compensation with the vesting of 9,812 RSUs scheduled for May 29, 2026, contingent on continuous service.

Industry Context

This Form 4 filing reports a routine equity compensation grant to a director, which is a common practice across various industries, including the biotechnology and pharmaceutical sectors where equity-based incentives are frequently used to align management and board interests with shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard form of equity compensation in publicly traded companies, aligning the director's financial interests with the company's stock performance.
• Without specific details on Exelixis's peer group compensation benchmarks or the total compensation package for its directors, a direct quantitative comparison to industry standards for this specific grant amount (9,812 RSUs) cannot be definitively assessed from this document alone.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Julie Smith, a Director of Exelixis, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders by tying a portion of her compensation to the company's stock performance. It also represents a minor potential future dilution upon vesting.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Vesting of 9,812 RSUs on May 29, 2026, subject to Julie Smith's continuous service.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Restricted Stock Units, RSU, Equity Incentive Plan, Director Compensation, Insider Transaction, Julie Smith